In­cyte grabs a new PD-1 check­point drug in $900M deal with Macro­Gen­ics

In­cyte $IN­CY has just inked a $900 mil­lion deal to grab glob­al rights to an ear­ly-stage PD-1 check­point now be­ing de­vel­oped at Macro­Gen­ics.

The two com­pa­nies an­nounced Wednes­day morn­ing that In­cyte will pay $150 mil­lion in a cash up­front for the de­vel­op­ment and com­mer­cial­iza­tion rights to MGA012, with Macro­Gen­ics hang­ing on to rights for run­ning com­bi­na­tion stud­ies us­ing their pipeline can­cer drug as­sets.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER